Cempra, Inc. to Present at JMP Securities Healthcare Conference

June 17, 2014 8:10 PM

7 0

CHAPEL HILL, N.C., June 17, 2014 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP) today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of Cempra, will present at the JMP Securities Healthcare Conference at 10:30 a.m. EDT, Tuesday, June 24, at The Westin New York Grand Central in New York City. Dr. Fernandes will discuss the company's two differentiated antibiotics, solithromycin (CEM-101) for community-acquired bacterial pneumonia and gonorrhea and Taksta(TM) (CEM-102 or fusidic acid) for oral treatment of chronic staphyloccoal infection including methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.

Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are currently in advanced clinical development. Solithromycin (CEM-101) is...

Read more

To category page

Loading...